Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,557,804 shares of SMMT stock, worth $129 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,557,804
Previous 6,557,927
0.0%
Holding current value
$129 Million
Previous $117 Million
8.13%
% of portfolio
0.02%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$481 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$229 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$156 Million0.0% of portfolio
-
State Street Corp Boston, MA4.85MShares$95.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$64.7 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.97B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...